Free Trial

BioLineRx Q1 2024 Earnings Report

BioLineRx logo
$0.10 +0.00 (+3.45%)
As of 04:00 PM Eastern

BioLineRx EPS Results

Actual EPS
-$0.01
Consensus EPS
-$0.29
Beat/Miss
Beat by +$0.28
One Year Ago EPS
-$0.15

BioLineRx Revenue Results

Actual Revenue
$6.86 million
Expected Revenue
$0.34 million
Beat/Miss
Beat by +$6.52 million
YoY Revenue Growth
N/A

BioLineRx Announcement Details

Quarter
Q1 2024
Time
Before Market Opens

Conference Call Resources

Conference Call Audio

BioLineRx Earnings Headlines

BioLineRx says current cash to provide runway through 2H26
Do this Before Elon’s Reveal on January 29th
Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.
BioLineRx Issues Letter to Shareholders
BioLineRx (NASDAQ:BLRX) Now Covered by StockNews.com
See More BioLineRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioLineRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioLineRx and other key companies, straight to your email.

About BioLineRx

BioLineRx (NASDAQ:BLRX), a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

View BioLineRx Profile

More Earnings Resources from MarketBeat